Neurologian klinikka
Department of Neurology

Julkaisut 1991
Publications 1991


1 Aaltonen M et al. Effects of THA on passive avoidance and spatial performance in quisqualic acid nucleus basalis-lesioned rats.
2 Airaksinen MM et al. Effects of alpha2-adrenoreceptor agonist and antagonist on spatial memory in rats.
3 Airaksinen MS et al. Histamine neurons in human hypothalamus: Anatomy in normal and Alzheimer diseased brains.
4 Alhainen K et al. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease.
5 Alhainen K et al. The effect of THA on cognitive functions and spectral power EEG in Alzheimer's disease: Preliminary results of on open study.
6 Alhainen K et al. Somatostatin and cognitive functions in Alzheimer's disease - the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine.
7 Alhainen KJ et al. Responders and nonresponders in experimental therapy of Alzheimer's disease.
8 Breteler MMB et al. Medical history and the risk of Alzheimer's disease: A collaborative re-analysis of case-control studies.
9 European Carotid Surgery Trialists' Collaborative Group et al. MCR European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis.
10 Freund TF et al. Pattern of neuronal death in the rat hippocampus after status epilepticus. Relationship to calcium binding protein content and ischemic vulnerability.
11 Graves AB et al. Occupational exposures to solvents and lead as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies.
12 Graves AB et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: A collaborative re-analysis of case control studies.
13 Gulyas AI et al. Subpopulations of GABAergic neurons containing parvalbumin, calbindin D28k, and cholecystokinin in the rat hippocampus.
14 Halonen T et al. Amino acid levels in cerebrospinal fluid of rats after administration of pentylenetetrazol.
15 Halonen T et al. Effects of vigabatrin (gamma-vinyl GABA) on neurotransmission-related aminoacids and on GABA and benzodiazepine receptor binding in rats.
16 Hartikainen P et al. Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.
17 Helkala EL et al. Slow-wave activity in the spectral analysis of the electroencephalogram is associated with cortical dysfunctions in patients with Alzheimer's disease.
18 Helkala EL et al. Different patterns of cognitive decline related to normal or deteriorating EEG in a 3-year follow-up study of patients with Alzheimer's disease.
19 Henriksson T et al. Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with monoclonal antibody-based immunoassay.
20 Jolkkonen J et al. A correlation study of CSF neuropeptides in Alzheimer's and Parkinson's disease.
21 Jorm AF et al. Psychiatric history and related exposures as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies.
22 Koponen H et al. Greutzfeldt-Jakobin taudin kaltainen oireisto mianseriinihoidon aikana.
23 Koponen H et al. Epileptic attack, delirium, and periodic complexes in the EEG during mianserin treatment.
24 Koponen H et al. Epileptic attack, delirium, and a Creutzfeldt-Jakob-like syndrome during mianserin treatment.
25 Koponen H, Riekkinen P. Acute confusional states in the elderly.
26 Koponen H, Riekkinen PJ. Clinical course and long-term prognosis of non-alcohol delirium in elderly patients.
27 Koponen H, Riekkinen PJ. Vanhusten sekavuustilojen pitkäaikaisennuste.
28 Koponen H, Riekkinen PJ. Cerebrospinal fluid acetylcholinesterase in patients with dementia associated with schizophrenia or chronic alcoholism.
29 Koponen H, Riekkinen PJ. Cerebrospinal fluid beta-endorphin-like immunoreactivity in patients with dementia associated with schizophrenia and chronic alcoholism.
30 Kälviäinen R et al. Randomized controlled pilot study of Vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy: an interim report.
31 Mortimer JA et al. Head trauma as a risk factor for Alzheimer's disease: A collaborative re-analysis of case-control studies.
32 Murros K. Stress reactions of brain infarction - A prospective study on 105 patients with acute ischemic brain infarction of the internal carotid artery territory.
33 Nousiainen U et al. Electromyographic findings in patients with Alzheimer's disease.
34 Pitkänen A, Amaral DG. Distribution on reduced nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) cells and fibers in the monkey amugdaloid complex.
35 Pitkänen A, Amaral DG. Demonstration of projections from the lateral nucleus to the basal nucleus of the amygdala: a PHA-L study in the monkey.
36 Reinikainen K et al. Neurotransmitter markers in the cerebrospinal fluid of patients with histologically verified Alzheimer's disease.
37 Riekkinen M et al. Comparison of quisqualic and ibotenic acid nucleus basalis magnocellularis lesions on water-maze and passive avoidance performance.
38 Riekkinen P Jr et al. Tetrahydroaminoacridine inhibits high voltage spindle activity in aged rats after acute and chronic treatment.
39 Riekkinen P Jr et al. Tetrahydroaminoacridine alleviates medial septal lesion-induced and age-related spatial reference but not working memory deficits.
40 Riekkinen P Jr et al. The effects of THA on scopolamine and nucleus basalis lesion-induced EEG slowing.
41 Riekkinen P Jr et al. The effects of increased serotonergic and decreased cholinergic activities on spatial navigation performance in rats.
42 Riekkinen P Jr et al. Joint modulation of neocortical electrical activity by nicotinic and muscarinic receptors.
43 Riekkinen P Jr et al. Combination of atipamezole and tetrahydroaminoacridine/pilocarpine treatment suppresses high voltage spindle activity in aged rats.
44 Riekkinen P Jr et al. Tetrahydroaminoacridine improves passive avoidance retention defects induced by aging and medial septal lesion but not by fimbria-fornix lesion.
45 Riekkinen P Jr et al. Comparison of the effects of acute and chronic ibotenic and quisqualic acid nucleus basalis lesioning.
46 Riekkinen P Jr et al. Increased GABAergic transmission aggravates nucleus basalis magnocellularis lesion-induced behavioral deficits.
47 Riekkinen P Jr et al. Effects of alpha2-drugs and pilocarpine on the high-voltage spindle activity of young and aged control and DSP4-lesioned rats.
48 Riekkinen P Jr et al. Alpha2-noradrenergic and basal forebrain cholinergic regulation of thalamic high-voltage spindles.
49 Riekkinen P Jr et al. Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basalis + frontal cortex-lesioned rats.
50 Riekkinen P Jr et al. EEG changes induced by acute and chronic quisqualic or ibotenic acid nucleus basalis lesions are stabilized by tacridine.
51 Riekkinen P Jr et al. Gammavinylgaba increases high voltage spindle activity in control and nucleus basalis-lesioned rats after sub-chronic treatment.
52 Riekkinen P Jr et al. Non-reversal of scopolamine- or age-related EEG changes by ondansetron, methysergide or alaproclate.
53 Riekkinen P Jr et al. Pharmacological consequences of cholinergic plus serotonergic manipulations.
54 Riekkinen P Jr et al. Effects of atipamezole and tetrahydroaminoacridine on nucleus basalis lesion-induced EEG changes.
55 Riekkinen P et al. The cholinergic system and EEG slow waves. Review article.
56 Rocca WA et al. Maternal age and Alzheimer's disease: A collaborative re-analysis of case-control studies.
57 Sirviö J et al. The effects of atipamezole, an alpha-2 antagonist, on the performance of young and aged rats in the delayed nonmatcing to position task.
58 Sirviö J et al. The molecular forms of acetylcholinesterase in cerebrospinal fluid of normal subjects - effect of aging.
59 Sirviö J et al. The effects of guanfacine, alpha-2 agonist, on the performance of young and aged rats in spatial navigation task.
60 Sirviö J et al. The effects of noradrenergic neurotoxin, DSP-4 on the performance of young and aged rats in spatial navigation task.
61 Sirviö J et al. 5th Nordic Neuroscience Meeting. Kuopio, June 12-15, 1991. Proceedings.
62 Sirviö J et al. The effect of subchronic administration of Vigabatrin on learning and memory in nonepileptic rats.
63 Sivenius J et al. Double-blind study of Gabapentin in the treatment of partial seizures.
64 Sivenius J et al. The European Stroke Prevention Study (ESPS): Results by arterial distribution.
65 Sivenius J et al. Antiplatelet therapy is effective in the prevention of stroke or death in women: subgroup analysis of the European stroke prevention study (ESPS).
66 Sivenius J et al. Vigabatrin in drug-resistant partial epilepsy: A 5-year follow-up study.
67 Sivenius J et al. Vigabatrin treatment of epilepsy - Reply from the authors.
68 Sivenius S et al. The European Stroke Prevention Study: Results according to sex.
69 Soikkeli R et al. Slowing of EEG in Parkinson's disease.
70 Soininen H et al. Cholinergic system and EEG: human studies.
71 Soininen H et al. Serial EEG in Alzheimer's disease: 3 year follow-up and clinical outcome.
72 Soininen H et al. Changes in absolute power values of EEG spectra in the follow-up of Alzheimer's disease.
73 Suomalainen T et al. Ohimolohkoepilepsian leikkaushoito.
74 Syrjänen S et al. Short biotinylated oligonucleotides bind non-specifically to senile plaques of Alzheimer's disease.
75 Valjakka A et al. Evoked field responses and awake immobility-related non-rhythmical EEG in hippocampus of young and aged rats.
76 Valjakka A et al. Evoked field responses, recurrent inhibition, long-term potentiation and immobility-related nonrhytmical EEG in the dentate gyrus of fimbria-fornix-lesioned and control rats.
77 Valjakka A et al. Modulation of EEG rhytmicity and spike activity in the rat hippocampus by systemically administered tetrahydroaminoacridine, scopolamine and atipamezole.
78 van Duijn CM et al. Familial aggregation of Alzheimer's disease and related disorders: A collaborative re-analysis of case-control studies.
79 Viinamäki H et al. Aivohalvauksen jälkeinen depressio.
80 Ylinen A. Hippocampal reactions and their pharmacotherapy in experimental epilepsy.
81 Ylinen A et al. Hippocampal mobility-related theta activity is not diminished by Vigabatrin, a GABAmimetic antiepileptic drug, in normal rats.
82 Ylinen A et al. Behavioural, electrophysiological and histopatological changes following sustained stimulation of the perforant pathway input to the hippocampus: effect of the NMDA receptor antagonist..
83 Ylinen A et al. Vigabatrin pre-treatment prevents hilar symatostatin cell loss and the development of interictal spiking activity following sustained simulation of the perforant path.
84 Ylinen EMA et al. Enhanced GABAergic inhibition preserves hippocampal structure and function in a model of epilepsy.

Neurologian klinikka Department of Neurology
Julkaisutietokanta 22.05.1997 Publications Data Base 22.05.1997